Proliferative vitreoretinopathy: does oral low-dose colchicine have an inhibitory effect? A controlled study in humans.
We investigated by means of a controlled prospective study, the effect of low dose oral colchicine (1.2 mg/day) on proliferative vitreoretinopathy (PVR) in humans. The PVR cases studied included ones associated with proliferative diabetic retinopathy, sickle retinopathy, trauma, and by venous occlusive disease. Applying Sandler's A statistic for correlated samples, we found no statistically significant difference between the results achieved in the colchicine group and those in the control group (vitamin C, 250 mg/day orally). We conclude that safe dosages of this drug do not significantly inhibit PVR.
Berman
D H
DH
Department of Ophthalmology, SUNY Downstate Medical Center, Brooklyn 11203.
Gombos
G M
GM
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001205:Ascorbic Acid / Q000627:therapeutic use; D003078:Colchicine / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008297:Male; D008875:Middle Aged; D010857:Pigment Epithelium of Eye / Q000187:drug effects; D011446:Prospective Studies; D012164:Retinal Diseases / Q000188:drug therapy*; D014792:Visual Acuity / Q000187:drug effects
D001205:Ascorbic Acid; D003078:Colchicine